Liver Neoplasm Clinical Trial
— PTHPOfficial title:
Feasibility of High Dose Proton Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: Prospective Phase II Trial
NCT number | NCT02571946 |
Other study ID # | 2015-06-053 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2015 |
Est. completion date | September 2021 |
Verified date | November 2023 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The standard treatment of advanced hepatocellular carcinoma (HCC) is sorafenib. Though the agent showed clear survival benefit in two randomized phase III trials, the benefit was modest and response rate was just a few percent. Therefore, other loco-regional modalities, like trans-arterial chemo-embolization (TACE), hepatic arterial infusion chemotherapy (HAIC), and radiotherapy (RT) were continuously tried, especially in locally advanced HCC including portal vein tumor thrombosis (PVTT). With the advancement of conformal RT techniques, RT was actively applied in HCC, especially in PVTT combined HCC. Many researchers reported that there is a relationship between RT dose and tumor response rate. RT dose, however, is frequently limited because the complications (like radiation induced liver disease (RILD), radiation induced gastro-duodenal toxicity, etc.) are also closely related with higher exposed RT dose. Proton beam has characteristic depth-dose distribution contrast to photon, the "Bragg peak". The advantage of this dose distribution could be more highlighted in HCC management, because of the weakness and maintenance importance of liver function itself in HCC patients. In fact, the superior results of proton beam therapy in HCC were constantly reported in several groups as prospectively as well as retrospectively. In those background, the investigators planned the present study to evaluate the efficacy and safety of proton beam therapy in HCC patients combined with PVTT.
Status | Completed |
Enrollment | 53 |
Est. completion date | September 2021 |
Est. primary completion date | September 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Hepatocellular carcinoma (HCC) patients - pathologically proven - HCC diagnosed based on American Association for the Study of Liver Diseases (AASLD) guideline - Portal vein tumor thrombosis (main, first branch, segmental) - Discussion in tumor board including gastroenterologist, radiologist, radiation oncologist - 20 or more age - Eastern Cooperative Oncology Group performance status 0 to 2 within 1 week before participate - Adequate bone marrow function (absolute neutrophil count = 1.0 x 109/l, platelet = 30 x 109/l, hemoglobin = 8 g/dl) - Adequate liver/renal function within 1 week before participate - Child-Pugh class A, B, or early C (score = 10) - Total bilirubin <3.0 mg/dL, Prothrombin time/International normalized ratio <1.7, Albumin=2.8g/dL, Aspartate aminotransferase/alanine aminotransferase<6 times of upper normal limit - Serum creatinine < 1,5 x upper normal limit, glomerular filtration rate > 50 ml/min Informed consent - Women of childbearing potential and male participants must agree to practice adequate contraception while on study and for at least 6 months following the last dose of RT and for at least 28 days following the last dose of sorafenib (whichever is later). Exclusion Criteria: - Uncontrolled hepatic encephalopathy - Previous history of upper abdominal radiotherapy - Status of pregnancy or breast feeding - Less than 12 weeks of expected survival - Uncontrolled ascites - Combined with disease known as radiosensitive disorder (connective tissue disorder, Ataxia-telangiectasia) - Hard to maintain stable respiration less than 5 minutes related with respiratory disease - Combined with uncontrolled severe acute disease other than liver |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | one-year overall survival | one-year after proton beam therapy | ||
Secondary | 1 month objective response rate | 1 month after proton beam therapy | ||
Secondary | 3 month objective response rate | 3 months after proton beam therapy | ||
Secondary | 1 month portal vein tumor thrombosis response rate | 1 month after proton beam therapy | ||
Secondary | 3 month portal vein tumor thrombosis response rate | 3 month after proton beam therapy | ||
Secondary | 1 year progression free survival | one-year after proton beam therapy | ||
Secondary | 1 year local progression free survival | one-year after proton beam therapy | ||
Secondary | 1 year portal vein tumor thrombosis progression free survival | one-year after proton beam therapy | ||
Secondary | Adverse event | one-year after proton beam therapy | ||
Secondary | 1 month Quality of life assessment compared with baseline | 1 month after proton beam therapy | ||
Secondary | 3 month Quality of life assessment compared with baseline | 3 month after proton beam therapy | ||
Secondary | 6 month Quality of life assessment compared with baseline | 6 month after proton beam therapy | ||
Secondary | Indocyanine green test change compared with baseline | 3 month after proton beam therapy | ||
Secondary | Hepatobiliary phase signal change after proton beam therapy | 3 month after proton beam therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02557724 -
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
|
||
Terminated |
NCT04702230 -
Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization
|
||
Active, not recruiting |
NCT01217034 -
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
|
Phase 2 | |
Recruiting |
NCT05169177 -
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
|
||
Withdrawn |
NCT02599909 -
Gut Microbiota in People With Hepatocellular Carcinoma (HCC)
|
||
Terminated |
NCT03998033 -
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
Recruiting |
NCT04010071 -
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
|
Phase 2 | |
Recruiting |
NCT04864054 -
T-Cell Therapy (ECT204) in Adults With Advanced HCC
|
Phase 2 | |
Terminated |
NCT04187937 -
Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections
|
N/A | |
Completed |
NCT02471313 -
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
|
Phase 2 | |
Completed |
NCT00001576 -
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
|
Phase 1 | |
Recruiting |
NCT01542281 -
Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer
|
N/A | |
Recruiting |
NCT03803436 -
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
|
Phase 2 | |
Completed |
NCT05495529 -
Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors
|
||
Recruiting |
NCT02632864 -
Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial
|
Phase 2 | |
Not yet recruiting |
NCT01180088 -
Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy
|
N/A | |
Withdrawn |
NCT00510627 -
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
|
Phase 4 | |
Completed |
NCT05848947 -
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
|
Phase 4 | |
Not yet recruiting |
NCT05723705 -
Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
|
||
Terminated |
NCT04502082 -
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
|
Phase 1/Phase 2 |